12:00 AM
Mar 06, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ISIS 14803: Began Phase I/II testing

Isis Pharmaceuticals Inc. (ISIP), Carlsbad, Calif.
Product: ISIS 14803
Business: Infectious diseases
Therapeutic category: Antisense
Target: Hepatitis C virus (HCV) RNA
Description: Phosphorothioate...

Read the full 93 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >